More Business Wire
View Older Stories View Newer Stories-
Franklin Templeton Closed-End Funds Announce Share Repurchases for the Third Quarter of 2023
-
InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
-
Citigroup Reports Third Quarter 2023 Results
-
ABION Presents New Efficacy Data for ABN401, a Novel MET TKI for Advanced Non-Small Cell Lung Cancer
-
Soluna Announces Implementation of 1-for-25 Reverse Stock Split
-
BioTools Innovator Names Limula 2023 Winner
-
Marcus & Millichap, Inc. to Report Third Quarter 2023 Financial Results on Friday, November 3, 2023
-
Comcast Expands Broadband Network to Pelahatchie, Mississippi
-
Dermavant Champions a Culture that Earns Three Best Workplace Rankings in 2023 by Fortune and Great Place to Work®
-
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy at Symposium on Hidradenitis Suppurativa Advances
-
FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers
-
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
-
The Bancorp, Inc. Sets Third Quarter 2023 Financial Results Release Date and Conference Call
-
Bright Health Group to Host Third Quarter 2023 Earnings Conference Call on November 7, 2023
-
Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen
-
SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa
-
Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cance
-
Power Integrations to Release Third-Quarter Financial Results on November 7
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Ex
-
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
-
CMCT Declares Preferred Stock Dividends
-
Bowman Acquires South Carolina Firm Dennis Corporation
-
Legends Real Estate Joins The Real Brokerage
-
The Cannabist Company to Report Third Quarter 2023 Results on November 14, 2023
-
Appalachian Regional Clean Hydrogen (ARCH2) Selected by the Department of Energy (DOE) to Develop Multi-State Clean Hydrogen Hub
-
Xcel Energy, Heartland Hydrogen Hub selected for up to $925 million federal award
-
JPMorgan Chase Reports Third-Quarter 2023 Financial Results
-
SunOpta Announces Sale of Frozen Fruit Assets for an Aggregate Purchase Price of $141 Million Along With Preliminary Results for Third Quarter Fiscal 2023 and CFO Transition
-
Covalon Presents Innovative Solutions Used in Top Hospitals at the Association for Vascular Access (AVA) Annual Scientific Meeting in Portland, OR
-
Capella University is Reaffirmed Among Select Institutions Offering Project Management Degree Programs
-
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
-
ZT Systems Unveils Future Cloud Computing Manufacturing Site in Greater Austin, Texas Area
-
Alliance Resource Partners, L.P. Announces Third Quarter 2023 Earnings Conference Call
-
Innovative Industrial Properties to Report 2023 Third Quarter Results
-
Wells Fargo Reports Third Quarter 2023 Financial Results
-
Birthright-Taglit Young Executive Forum Addresses Concerns to McGill University Regarding Responses to Violent Conflicts
-
Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
-
Birthright-Taglit Young Executive Forum Expresses Grave Concern Over Starbucks Union’s Endorsement of Violent Acts
-
Vertex Energy Provides Operational Update for Third Quarter 2023
-
Terran Orbital Opens New Printed Circuit Board Assembly Facility
-
BlackRock Reports Third Quarter 2023 Earnings
-
Defiance's Suite of Daily Options (0DTE) Income ETFs, $QQQY & $JEPY, Surpass $100M AUM in less than 30 Days
-
NW Natural Holdings Schedules Earnings Release and Conference Call for Friday, November 3
-
Five Point Holdings, LLC Sets Date for Third Quarter 2023 Earnings Announcement and Investor Conference Call
-
UnitedHealth Group Reports Third Quarter 2023 Results
-
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
-
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
-
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine¹
-
Tikehau Capital: Disclosure of Shares Repurchases From 6 October to 12 October 2023
-
AM Best Europe Insurance Market Briefing to Examine State of Industry Amid Escalating Challenges; Beazley CEO to Deliver Keynote

